Australia markets close in 4 hours 44 minutes

Oculis Holding AG (OCS)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
11.90-0.08 (-0.67%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.98
Bid11.88 x 200
Ask12.00 x 100
Day's range11.90 - 12.00
52-week range9.05 - 14.50
Avg. volume40,275
Market cap495.631M
Beta (5Y monthly)0.13
PE ratio (TTM)66.11
EPS (TTM)0.18
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.08
  • Simply Wall St.

    While institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownership

    Key Insights Oculis Holding's significant individual investors ownership suggests that the key decisions are influenced...

  • GlobeNewswire

    Oculis updates share capital for its existing at-the-market offering program

    ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 1,000,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 46,443,7

  • GlobeNewswire

    Oculis Reports Q1 2024 Financial Results and Provides Company Updates

    Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. p